NCT07094568Recruiting
Tirzepatide vs Liraglutide in Bone
Comparative Investigation of Changes in Body Composition and Bone Turnover Markers in People With Obesity After Treatment With Tirzepatide Versus Liraglutide. A Prospective Cohort Study.
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
This prospective cohort study investigates the effects of tirzepatide versus liraglutide on bone turnover markers and body composition in adults with class 3 obesity, characterised by Body Mass Index (BMI) ≥40 kg/m². Participants will be followed for 6 months with assessments at baseline, 3 and 6. The primary outcome is the change in bone resorption marker C-terminal telopeptide of type I collagen (CTX) at 3 months. Secondary outcomes include changes in body weight, BMI, bone mineral density (BMD), and body composition. The study aims to clarify the differential impact of weight loss achieved through tirzepatide versus liraglutide on bone metabolism and body composition in adults with obesity.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 72 (estimated)
- First submitted
- 30 Jun 2025
- Start date
- May 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- National and Kapodistrian University of Athens
- Diseases
- Obesity
- NCT number
- NCT07094568
What you commit to
- Study type: Observational
- Planned participants: 72
- From May 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous bariatric or gastrointestinal surgery involving intestinal bypass
- Medications which can affect bone markers: bone-anabolic agents, antiresorptive agents, antiandrogenic agents, vitamin K antagonists, antipsychotic agents, contraceptives, glucocorticoids (oral), methotrexate, thiazides, aromatase inhibitors etc)
Other illness
- Type 2 Diabetes Mellitus (T2DM) and type 1 Diabetes Mellitus (T1DM)
- Chronic kidney disease
- Liver failure
- Heart failure
- Malignancy coexistence
- Rare Metabolic Bone Diseases (e.g., Paget's disease of bone, fibrous dysplasia, osteopetrosis)
Other
- Uncontrolled hypo/hyperthyroidism
- Uncontrolled hypo/hyperparathyroidism
- Pregnancy and lactation
- Recent fracture (within 2 years)
- Inflammatory arthritis
- Hemolytic anemia
Who the study is looking for
- Adults aged between 30 and 65 years
- BMI ≥40 kg/m²
Age in the registry: 30 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Laiko General Hospital Coordinator of this site? Confirm its status | Athens | Greece | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.